- Home
- MIN vs BNTC Comparison
MIN vs BNTC Comparison
Compare MIN & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- BNTC
- Stock Information
- Founded
- MIN 1988
- BNTC 1995
- Country
- MIN United States
- BNTC United States
- Employees
- MIN N/A
- BNTC N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- BNTC Health Care
- Exchange
- MIN Nasdaq
- BNTC Nasdaq
- Market Cap
- MIN 305.0M
- BNTC 339.8M
- IPO Year
- MIN N/A
- BNTC N/A
- Fundamental
- Price
- MIN $2.69
- BNTC $14.97
- Analyst Decision
- MIN
- BNTC Strong Buy
- Analyst Count
- MIN 0
- BNTC 7
- Target Price
- MIN N/A
- BNTC $24.43
- AVG Volume (30 Days)
- MIN 331.0K
- BNTC 33.7K
- Earning Date
- MIN 01-01-0001
- BNTC 05-12-2025
- Dividend Yield
- MIN 7.31%
- BNTC N/A
- EPS Growth
- MIN N/A
- BNTC N/A
- EPS
- MIN 0.08
- BNTC N/A
- Revenue
- MIN N/A
- BNTC N/A
- Revenue This Year
- MIN N/A
- BNTC N/A
- Revenue Next Year
- MIN N/A
- BNTC N/A
- P/E Ratio
- MIN $33.38
- BNTC N/A
- Revenue Growth
- MIN N/A
- BNTC N/A
- 52 Week Low
- MIN $2.52
- BNTC $4.75
- 52 Week High
- MIN $2.88
- BNTC $15.29
- Technical
- Relative Strength Index (RSI)
- MIN 48.56
- BNTC 70.53
- Support Level
- MIN $2.66
- BNTC $11.99
- Resistance Level
- MIN $2.72
- BNTC $13.00
- Average True Range (ATR)
- MIN 0.02
- BNTC 1.03
- MACD
- MIN -0.00
- BNTC 0.34
- Stochastic Oscillator
- MIN 44.00
- BNTC 94.17
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.